Neovascularization, Corneal, CL-related Medication

Updated: Aug 19, 2015
  • Author: Barry A Weissman, OD, PhD, FAAO; Chief Editor: Hampton Roy, Sr, MD  more...
  • Print
Medication

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Next:

Corticosteroids

Class Summary

Usually decrease inflammation that aggravates neovascularization.

Prednisolone ophthalmic (Omnipred, Pred Forte, Pred Mild)

Effective topical ophthalmic steroid use decreases the angiogenic effect during NV. The steroids decrease inflammation by reducing capillary permeability and cellular exudation, suppress lymphocytic proliferation, inhibit phospholipase A synthesis, and inhibit cell-mediated immune responses. Use of steroids is limited for short-term use only owing to the many side effects, including cataracts and glaucoma. Milder steroids such as loteprednol have lower risks of cataracts and glaucoma and are preferred over stronger steroids in these patients.

Loteprednol ophthalmic (Alrex, Lotemax)

Prevents inflammation by inhibiting capillary dilation, leukocyte formation, and edema. It is a mild corticosteroid with lower risks of developing cataracts and glaucoma and is preferred over stronger steroids in these patients.

Previous
Next:

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Class Summary

Anti-VEGF antibodies bind and inactivate VEGF, which is an important mediator of angiogenesis that is upregulated during neovascularization. Anti-VEGF agents show promise in the treatment of severe corneal neovascularization though perhaps are excessive for contact lens–induced NV.

Bevacizumab (Avastin)

Monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF). The binding of the monoclonal antibody to VEGF may inhibit the formation of new blood vessels, which may in turn reduce the growth of all tissues.

Ranibizumab (Lucentis)

Monoclonal antibody that binds to and neutralizes vascular endothelial growth factor A (VEGF-A). The binding of the monoclonal antibody to VEGF may inhibit the formation of new blood vessels, which may in turn reduce the growth of all tissues.

Previous